BOSULIF 100 mg/1 (Bosutinib CAPSULE) 100 mg/1

Bosutinib 100 mg capsules are a pharmaceutical product used for targeted therapy. This medication is designed to interact with specific proteins in the body, supporting various treatment protocols.

Strength

100 mg/1

Pack Size

150 CAPSULE in 1 BOTTLE (0069-1014-15)

Manufacturer / TM Owner

Pfizer Laboratories Div Pfizer Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bosutinib is primarily used in the management of certain types of cancer. It works by targeting specific proteins involved in the growth and spread of cancer cells. Patients often wonder, 'What is Bosutinib used for?' This medication is typically prescribed for conditions where these proteins play a critical role.

Side Effects

Common effects of Bosutinib may include gastrointestinal issues such as nausea, diarrhea, and vomiting. Some users also report fatigue and changes in appetite. These effects can vary widely among individuals and are not experienced by everyone taking the medication.

Precautions & Warnings

Bosutinib should be handled with care, following the guidelines provided by healthcare professionals. It is important to store the medication properly and to follow any specific instructions related to its use. Always consult with a healthcare provider before starting or stopping any medication.

Avoid Interactions

Bosutinib may interact with certain foods, supplements, and other medications. It is advisable to discuss all current medications and supplements with a healthcare provider to avoid potential interactions. Alcohol and other substances may also affect how Bosutinib works in the body.

Frequently Asked Questions

Bosutinib is used in the treatment of certain types of cancer by targeting specific proteins involved in cancer cell growth.

Bosutinib is typically taken orally, and the specific instructions for administration should be provided by a healthcare professional.

Common side effects may include gastrointestinal issues such as nausea, diarrhea, and vomiting, as well as fatigue and changes in appetite.

Bosutinib may interact with other medications, so it is important to discuss all current medications with a healthcare provider.

Bosutinib should be stored according to the instructions provided by the manufacturer, typically in a cool, dry place.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.